© Reuters. FILE PHOTO: Check tubes are seen in entrance of Amylyx brand on this illustration, July 24, 2022. REUTERS/Dado Ruvic/Illustration/File Picture
(Reuters) -Amylyx Prescribed drugs Inc stated on Friday it has set the record value of its newly accredited drug to gradual the development of amyotrophic lateral sclerosis (ALS) at about $158,000 per yr in america.
The drug has been priced at round $12,500 per 28-day prescription, ensuing within the wholesale value of $158,000 per yr, Chief Industrial Officer Margaret Olinger stated in an traders’ convention name, including that the value is beneath Japanese agency Mitsubishi Tanabe’s Radicava — essentially the most just lately accredited drug by the Meals and Drug Administration (FDA).
“We imagine that the value chosen balances the wants of and enter from the ALS neighborhood and will likely be supported by insurers” Olinger stated.
Amylyx additionally plans to offer the drug, which will likely be offered beneath the model title Relyvrio, for free of charge to ALS sufferers within the U.S. which can be uninsured or underinsured, in the event that they meet sure monetary eligibility standards and have exhausted all different choices, Olinger stated.
The drug was accredited by the U.S. FDA on Thursday, making it the third ALS drug to be given a nod by the regulator after Mitsubishi Tanabe’s Radicava and the generic drug riluzole.